nodes	percent_of_prediction	percent_of_DWPC	metapath
Valganciclovir—SLC6A14—Amino acid transport across the plasma membrane—SLC3A1—nephrolithiasis	0.0521	0.0784	CbGpPWpGaD
Valganciclovir—SLC6A14—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0361	0.0544	CbGpPWpGaD
Valganciclovir—SLC6A14—Amino acid transport across the plasma membrane—SLC7A9—nephrolithiasis	0.0327	0.0492	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.0233	0.035	CbGpPWpGaD
Valganciclovir—SLC6A14—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.0227	0.0341	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.0213	0.032	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.0213	0.032	CbGpPWpGaD
Valganciclovir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0171	0.0257	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.0161	0.0243	CbGpPWpGaD
Valganciclovir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0159	0.0239	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.0159	0.0239	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.015	0.0225	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.0147	0.0222	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.0134	0.0201	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.011	0.0166	CbGpPWpGaD
Valganciclovir—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0321	CcSEcCtD
Valganciclovir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.0107	0.0161	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC2A9—nephrolithiasis	0.0106	0.016	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0104	0.0156	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.0102	0.0154	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.0101	0.0151	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.0101	0.0151	CbGpPWpGaD
Valganciclovir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.00996	0.015	CbGpPWpGaD
Valganciclovir—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.00962	0.0287	CcSEcCtD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00951	0.0143	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00951	0.0143	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00934	0.014	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00934	0.014	CbGpPWpGaD
Valganciclovir—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00895	0.0267	CcSEcCtD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00763	0.0115	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00721	0.0108	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00721	0.0108	CbGpPWpGaD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00709	0.0107	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00708	0.0106	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0067	0.0101	CbGpPWpGaD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0067	0.0101	CbGpPWpGaD
Valganciclovir—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.0067	0.02	CcSEcCtD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00658	0.0099	CbGpPWpGaD
Valganciclovir—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.0065	0.0194	CcSEcCtD
Valganciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00632	0.00951	CbGpPWpGaD
Valganciclovir—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00622	0.0186	CcSEcCtD
Valganciclovir—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00605	0.0181	CcSEcCtD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00597	0.00898	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00593	0.00892	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00593	0.00892	CbGpPWpGaD
Valganciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00587	0.00882	CbGpPWpGaD
Valganciclovir—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00553	0.0165	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00529	0.00795	CbGpPWpGaD
Valganciclovir—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00528	0.0158	CcSEcCtD
Valganciclovir—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00518	0.0155	CcSEcCtD
Valganciclovir—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00509	0.0152	CcSEcCtD
Valganciclovir—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00505	0.0151	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00492	0.0074	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00483	0.00727	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00483	0.00727	CbGpPWpGaD
Valganciclovir—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00481	0.0143	CcSEcCtD
Valganciclovir—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00481	0.0143	CcSEcCtD
Valganciclovir—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00477	0.0142	CcSEcCtD
Valganciclovir—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00473	0.0141	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00457	0.00686	CbGpPWpGaD
Valganciclovir—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00452	0.0135	CcSEcCtD
Valganciclovir—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.0045	0.0134	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0045	0.00676	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0045	0.00676	CbGpPWpGaD
Valganciclovir—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00441	0.0132	CcSEcCtD
Valganciclovir—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00439	0.0131	CcSEcCtD
Valganciclovir—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00437	0.0131	CcSEcCtD
Valganciclovir—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00433	0.0129	CcSEcCtD
Valganciclovir—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00425	0.0127	CcSEcCtD
Valganciclovir—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00418	0.0125	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00418	0.00628	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00418	0.00628	CbGpPWpGaD
Valganciclovir—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00415	0.0124	CcSEcCtD
Valganciclovir—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00415	0.0124	CcSEcCtD
Valganciclovir—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00407	0.0122	CcSEcCtD
Valganciclovir—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00388	0.0116	CcSEcCtD
Valganciclovir—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00388	0.0116	CcSEcCtD
Valganciclovir—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00386	0.0115	CcSEcCtD
Valganciclovir—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00384	0.0115	CcSEcCtD
Valganciclovir—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00383	0.0114	CcSEcCtD
Valganciclovir—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00379	0.0113	CcSEcCtD
Valganciclovir—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00375	0.0112	CcSEcCtD
Valganciclovir—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00373	0.0111	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00366	0.00551	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00366	0.00551	CbGpPWpGaD
Valganciclovir—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00364	0.0109	CcSEcCtD
Valganciclovir—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00363	0.0108	CcSEcCtD
Valganciclovir—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00361	0.0108	CcSEcCtD
Valganciclovir—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.0036	0.0107	CcSEcCtD
Valganciclovir—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00353	0.0105	CcSEcCtD
Valganciclovir—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00347	0.0104	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00341	0.00513	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00341	0.00513	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00341	0.00512	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00341	0.00512	CbGpPWpGaD
Valganciclovir—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00332	0.00993	CcSEcCtD
Valganciclovir—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.0033	0.00985	CcSEcCtD
Valganciclovir—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00328	0.00978	CcSEcCtD
Valganciclovir—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.0032	0.00957	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00317	0.00477	CbGpPWpGaD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00317	0.00477	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00316	0.00476	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00316	0.00476	CbGpPWpGaD
Valganciclovir—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.0031	0.00926	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00304	0.00456	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00304	0.00456	CbGpPWpGaD
Valganciclovir—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00887	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00294	0.00442	CbGpPWpGaD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00294	0.00442	CbGpPWpGaD
Valganciclovir—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00294	0.00877	CcSEcCtD
Valganciclovir—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00285	0.00852	CcSEcCtD
Valganciclovir—Tension—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00848	CcSEcCtD
Valganciclovir—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00283	0.00846	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00283	0.00425	CbGpPWpGaD
Valganciclovir—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00281	0.00839	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0028	0.00422	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0028	0.00422	CbGpPWpGaD
Valganciclovir—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00836	CcSEcCtD
Valganciclovir—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00278	0.00831	CcSEcCtD
Valganciclovir—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00273	0.00814	CcSEcCtD
Valganciclovir—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00271	0.0081	CcSEcCtD
Valganciclovir—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00269	0.00802	CcSEcCtD
Valganciclovir—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00799	CcSEcCtD
Valganciclovir—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00266	0.00794	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00262	0.00394	CbGpPWpGaD
Valganciclovir—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00779	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0026	0.00391	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0026	0.00391	CbGpPWpGaD
Valganciclovir—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00776	CcSEcCtD
Valganciclovir—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00259	0.00774	CcSEcCtD
Valganciclovir—Cough—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00754	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.0025	0.00376	CbGpPWpGaD
Valganciclovir—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00246	0.00736	CcSEcCtD
Valganciclovir—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00246	0.00733	CcSEcCtD
Valganciclovir—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00243	0.00727	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00243	0.00365	CbGpPWpGaD
Valganciclovir—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00241	0.0072	CcSEcCtD
Valganciclovir—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00711	CcSEcCtD
Valganciclovir—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00236	0.00705	CcSEcCtD
Valganciclovir—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00236	0.00705	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00232	0.00349	CbGpPWpGaD
Valganciclovir—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00231	0.00691	CcSEcCtD
Valganciclovir—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00231	0.00688	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00229	0.00344	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00229	0.00344	CbGpPWpGaD
Valganciclovir—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00228	0.00682	CcSEcCtD
Valganciclovir—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00225	0.00672	CcSEcCtD
Valganciclovir—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00221	0.00659	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00643	CcSEcCtD
Valganciclovir—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00638	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00212	0.00319	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00212	0.00319	CbGpPWpGaD
Valganciclovir—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00212	0.00633	CcSEcCtD
Valganciclovir—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00211	0.00629	CcSEcCtD
Valganciclovir—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00627	CcSEcCtD
Valganciclovir—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00208	0.00621	CcSEcCtD
Valganciclovir—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00613	CcSEcCtD
Valganciclovir—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00204	0.00608	CcSEcCtD
Valganciclovir—Pain—Hydrochlorothiazide—nephrolithiasis	0.00202	0.00603	CcSEcCtD
Valganciclovir—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00202	0.00603	CcSEcCtD
Valganciclovir—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00195	0.00581	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00577	CcSEcCtD
Valganciclovir—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00188	0.0056	CcSEcCtD
Valganciclovir—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00558	CcSEcCtD
Valganciclovir—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00558	CcSEcCtD
Valganciclovir—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00174	0.0052	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00173	0.00261	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00173	0.00261	CbGpPWpGaD
Valganciclovir—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00169	0.00506	CcSEcCtD
Valganciclovir—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00167	0.00499	CcSEcCtD
Valganciclovir—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00162	0.00483	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00161	0.00242	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00161	0.00242	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00161	0.00242	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00161	0.00242	CbGpPWpGaD
Valganciclovir—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00156	0.00466	CcSEcCtD
Valganciclovir—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.0015	0.00448	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00149	0.00225	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00149	0.00225	CbGpPWpGaD
Valganciclovir—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00149	0.00444	CcSEcCtD
Valganciclovir—Headache—Hydrochlorothiazide—nephrolithiasis	0.00148	0.00442	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00144	0.00216	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00144	0.00216	CbGpPWpGaD
Valganciclovir—Nausea—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00419	CcSEcCtD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00133	0.002	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00133	0.002	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00115	0.00173	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00107	0.0016	CbGpPWpGaD
